Low-dose methotrexate in therapy-resistant lichen sclerosus: first clinical experience with recurrence-free interval extension in HPV-independent vulvar intraepithelial neoplasia (HPVi VIN)

Clicks: 41
ID: 326617
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #36 of 412 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 412 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Low-dose methotrexate (MTX) has been used for corticosteroid-refractory lichen sclerosus, but its effect on differentiated vulvar intraepithelial neoplasia (dVIN) recurrence has never been reported. In this first multicenter within-patient observational study, all six continuing patients exceeded their shortest pre-MTX recurrence-free interval, and three achieved sustained reduction in topical corticosteroid use. These findings support prospective evaluation in the MERCURE trial and provide a rationale for MTX as a non-surgical treatment option in recurrent, therapy-resistant dVIN.
Reference Key
openalex_W7204575966 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag364
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.